secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001493152-24-020973
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics reports zero clinically-relevant adverse events in Phase 1 single dose portion for PT00114
--------------------------------------------------------------------------------

- Phase 1 single dose trial completed with 30 subjects across five cohorts up to 1,000 micrograms; no clinically-relevant adverse events.
- Multiple ascending dose portion of the trial is planned to commence later this year.
- PT00114 targets stress reduction as root cause for PTSD, depression, anxiety, addiction, and potentially obesity.
- Investor call scheduled for May 22 at 10:00 am ET to discuss safety data and implications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315224020973/0001493152-24-020973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315224020973/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer